Compare · CI vs TLSI
CI vs TLSI
Side-by-side comparison of The Cigna Group (CI) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $74.45B, about 282.6x TLSI ($263.5M).
- Over the past year, CI is down 4.5% and TLSI is down 5.9% - CI leads by 1.5 points.
- TLSI has been more active in the news (9 items in the past 4 weeks vs 7 for CI).
- CI has more recent analyst coverage (25 ratings vs 6 for TLSI).
- Company
- The Cigna Group
- TriSalus Life Sciences Inc.
- Price
- -
- -
- Market cap
- $74.45B
- $263.5M
- 1M return
- -3.62%
- +3.00%
- 1Y return
- -4.46%
- -5.92%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 9
- Recent ratings
- 25
- 6
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CI
- New insider Holgerson Bryan claimed ownership of 7,693 shares (SEC Form 3)
- New insider Kautzner Adam claimed ownership of 13,533 shares (SEC Form 3)
- New insider Sadler Jason D claimed ownership of 34,705 shares (SEC Form 3)
- New insider Sanford Paul A claimed ownership of 4,073 shares (SEC Form 3)
- New insider Perlberg Matthew claimed ownership of 9,345 shares (SEC Form 3)
- The Cigna Group's Second Quarter 2026 Earnings Release Details
- Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions
- The Cigna Group Foundation Honors David M. Cordani's Leadership with New Grant to Strengthen Military Communities
- SEC Form 11-K filed by The Cigna Group
- The Cigna Group Foundation Invests $3 Million to Strengthen Youth Mental Health Through Nonprofits Across 10 States
Latest TLSI
- TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Financial Officer Patience David covered exercise/tax liability with 14,650 shares, decreasing direct ownership by 5% to 261,107 units (SEC Form 4) (tax liability)
- CEO and President Szela Mary T was granted 3,990 shares, increasing direct ownership by 0.37% to 1,077,683 units (SEC Form 4)
- Szela Mary T increased direct ownership by 101% to 1,023,826 units (SEC Form 5)
- Chief Commercial Officer Marshak Richard was granted 561 shares, increasing direct ownership by 0.44% to 128,319 units (SEC Form 4)
- Marshak Richard increased direct ownership by 383% to 131,758 units (SEC Form 5)
- Chief Medical Officer Marshall Richard Henry was granted 60,000 shares, increasing direct ownership by 200% to 90,000 units (SEC Form 4)
- New insider Marshall Richard Henry claimed ownership of 30,000 shares (SEC Form 3)
- TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer